BILLERICA, Mass. , Aug. 02, 2018 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS), a medical technology company that uses its proprietary iFit Image-to-Implant technology platform to develop, manufacture and sell joint replacement implants that are customized to fit each patient's unique anatomy,

The most advanced, patient conforming hip replacement system designed to enhance operational efficiency for the surgeon and improve patient outcomes BILLERICA, Mass., Aug. 01, 2018 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS), a medical technology company that offers patient conforming joint

BILLERICA, Mass. , Aug. 01, 2018 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS), a medical technology company that uses its proprietary iFit Image-to-Implant technology platform to develop, manufacture and sell patient specific joint replacement implants designed to fit each patient's unique

BILLERICA, Mass. , July 12, 2018 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS) announced today that it will host a webcast on Wednesday, August 1, 2018 , at 4:30 p.m. Eastern Time to discuss its financial results for the second quarter 2018.  The webcast will be live at:

Manuscript highlights the intraoperative compromises of fit vs. rotation with the legacy off-the-shelf knee implants BILLERICA, Mass., June 25, 2018 (GLOBE NEWSWIRE) -- Conformis Inc. (NASDAQ:CFMS), a medical technology company that uses its proprietary iFit Image-to-Implant technology platform to

BILLERICA, Mass. , May 02, 2018 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS), a medical technology company that uses its proprietary iFit Image-to-Implant technology platform to develop, manufacture and sell joint replacement implants that are customized to fit each patient's unique anatomy,

BILLERICA, Mass. , April 12, 2018 (GLOBE NEWSWIRE) -- ConforMIS, Inc. (NASDAQ:CFMS) announced today that it will host a conference call on Wednesday, May 2, 2018 , at 4:30 p.m. Eastern Time to discuss its financial results for the first quarter 2018.  To participate in the conference call, please

Data Shows a Low Cumulative Percent Revision of 0.5% for Conformis Patients vs 1.9% for all Total Knee Replacement Patients BILLERICA, Mass. , March 07, 2018 (GLOBE NEWSWIRE) -- Conformis , Inc. (NASDAQ:CFMS), a medical technology company that offers joint replacement implants designed and

Rating highlights positive three-year survivorship following total knee arthroplasty BILLERICA, Mass., March 01, 2018 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS), a medical technology company that offers joint replacement implants designed and manufactured to fit and conform to each patient's

BILLERICA, Mass. , Feb. 07, 2018 (GLOBE NEWSWIRE) -- ConforMIS, Inc. (NASDAQ:CFMS), a medical technology company that uses its proprietary iFit Image-to-Implant technology platform to develop, manufacture and sell joint replacement implants that are customized to fit each patient's unique anatomy,

BILLERICA, Mass. , Jan. 25, 2018 (GLOBE NEWSWIRE) -- ConforMIS ,  Inc. (NASDAQ:CFMS), a medical technology company that uses its proprietary iFit Image-to-Implant technology platform to develop, manufacture and sell joint replacement implants that are customized to fit each patient's unique

BILLERICA, Mass. , Jan. 24, 2018 (GLOBE NEWSWIRE) -- ConforMIS, Inc. (NASDAQ:CFMS), a medical technology company that uses its proprietary iFit Image-to-Implant technology platform to develop, manufacture and sell joint replacement implants that are customized to fit each patient's unique anatomy,

ConforMIS to Host Fourth Quarter and the Year Ended 2017 Financial Results Conference Call and Webcast on February 7, 2018 BILLERICA, Mass. , Jan. 08, 2018 (GLOBE NEWSWIRE) -- ConforMIS, Inc. (NASDAQ:CFMS), a medical technology company that uses its proprietary iFit Image-to-Implant technology

BILLERICA, Mass., Jan. 04, 2018 (GLOBE NEWSWIRE) -- ConforMIS, Inc. (NASDAQ:CFMS), a medical technology company that offers joint replacement implants designed and manufactured to fit each patient’s unique anatomy, today announced the publication of a prospective study in The Journal of Knee